SEC filing record
Primary Source · SEC.gov

Areteia Therapeutics, Inc.

2022 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalSold increasedForm D/A · 2025-02-217 events: 2 sold increased, 2 investors increased, 2 large raiseLast filing 2025-02-21

Raised

$360M

Investors

16

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Areteia Therapeutics, Inc. is a Delaware corporation that first filed a Form D on July 14, 2022 and most recently amended it on February 21, 2025 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Areteia Therapeutics, Inc. reported $360,000,020 sold from 16 investors of a $445,000,000 total offering as of the Form D filed February 21, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names COWEN AND COMPANY, LLC (CRD 7616), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $13,025,000 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 101 Glen Lennox Dr., Suite 300, Chapel Hill, NC 27517.

Critical Disclosures

What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.

Reporting lapsed · Form D · last filing February 21, 2025

Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.

Timeline
Each line is a fact as filed. The history behind it, the same event across other issuers, and an alert on the next one:Open in the terminal Watch this issuer

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001937542
Entity NameAreteia Therapeutics, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address101 Glen Lennox Dr., Suite 300, Chapel Hill, NC 27517
Phone(617) 504-0362
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateJune 15, 2022
Filing DateFebruary 21, 2025
Accession Number0001937542-25-000001
Total Offering Amount$445,000,000
Total Amount Sold$360,000,020
Amount Remaining$84,999,980
Total Investors16
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationIntended to last more than one year
Sales Commissions$13,025,000 (to COWEN AND COMPANY, LLC)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)NC
Amendment Count3 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

7

latest Feb 21, 2025

Critical / warning

0 / 0

5 watch · 2 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

dark

Latest event Sold increase · Feb 21, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 7 filing events with values and deltas, latest 2025-02-21, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Paul Berns

Director · Chapel Hill, NC

Adam Koppel

Director · Chapel Hill, NC

Ian Read

Director · Chapel Hill, NC

Benjamin Gomez

Director · Chapel Hill, NC

Michael E. Bozik

Director · Chapel Hill, NC

Stephen E. Butts

Director · Chapel Hill, NC

Jorge E. Bartolome

Executive Officer, Director · Chapel Hill, NC

Elyse E. Stock

Director · Chapel Hill, NC

Daniel E. Becker

Director · Chapel Hill, NC

Christopher E. Courts

Executive Officer · Chapel Hill, NC

Robin E. Walker

Executive Officer · Chapel Hill, NC

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

COWEN AND COMPANY, LLCCRD 7616 on BrokerCheck

Associated broker-dealer: None · NEW YORK, NY · Soliciting in all states

Questions About Areteia Therapeutics, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Areteia Therapeutics, Inc.?

Areteia Therapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on February 21, 2025 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is Areteia Therapeutics, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Areteia Therapeutics, Inc. filed a Form D with the SEC on February 21, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $360,000,020 sold to 16 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Areteia Therapeutics, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Areteia Therapeutics, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Areteia Therapeutics, Inc. raised?

Areteia Therapeutics, Inc. reported $360,000,020 sold from 16 investors of a $445,000,000 total offering as of the Form D filed February 21, 2025.

Who can invest in Areteia Therapeutics, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Areteia Therapeutics, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Areteia Therapeutics, Inc. and how are they paid?

The Form D names COWEN AND COMPANY, LLC (CRD 7616), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $13,025,000 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Areteia Therapeutics, Inc.?

The Form D lists 11 related persons: Paul Berns, director; Adam Koppel, director; Ian Read, director; Benjamin Gomez, director; Michael E. Bozik, director; Stephen E. Butts, director; Jorge E. Bartolome, executive officer, director; Elyse E. Stock, director, and 3 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Areteia Therapeutics, Inc. located?

The issuer's address on its SEC filings is 101 Glen Lennox Dr., Suite 300, Chapel Hill, NC 27517. Its phone number of record is 617-504-0362. It is organized under the laws of Delaware.

How long is the Areteia Therapeutics, Inc. offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.

What is Areteia Therapeutics, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.